SCHEMBL6035663

SCHEMBL6035663

O=C(O)c1cccc(OCCCc2cc(-c3ccc(C(F)(F)F)cc3)no2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY14 Q15391 4/20 0.49
TSPO P30536 2/20 0.49
CYP2C9 P11712 1/20 0.49
TMEM97 Q5BJF2 1/20 0.49
SIGMAR1 Q99720 1/20 0.49
NR4A2 P43354 2/20 0.47
MRGPRX4 Q96LA9 3/20 0.46
HRH1 P35367 1/20 0.46
OPRD1 P41143 1/20 0.46
PPARD Q03181 2/20 0.46
MAPT P10636 2/20 0.45
TP53 P04637 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ALDH1A1 P00352 1/20 0.44
KMT2A Q03164 1/20 0.44
MAOB P27338 1/20 0.43
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
LTB4R Q15722 2/20 0.41
NR4A1 P22736 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6034664 0.89 P2RY14 (0.53) P2RY14TSPOCYP2C9TMEM97SIGMAR1
SCHEMBL6034453 0.88 P2RY14 (0.52) P2RY14TSPOCYP2C9TMEM97SIGMAR1
SCHEMBL6035641 0.86 PPARD (0.47) P2RY14TSPOCYP2C9TMEM97SIGMAR1
SCHEMBL6035247 0.85 PPARD (0.46) P2RY14TSPOCYP2C9TMEM97SIGMAR1
SCHEMBL6034580 0.81 PPARD (0.48) P2RY14TSPOCYP2C9TMEM97SIGMAR1
SCHEMBL6035653 0.81 PPARD (0.50) P2RY14TSPOCYP2C9TMEM97SIGMAR1
SCHEMBL6034590 0.80 PPARD (0.49) P2RY14TSPOCYP2C9TMEM97SIGMAR1
SCHEMBL6034613 0.80 FFAR1 (0.58) PPARDPPARGPPARA
SCHEMBL6035565 0.79 FFAR1 (0.57) PPARDPPARGPPARALTB4R
SCHEMBL14269432 0.79 PPARD (0.45) P2RY14TSPOCYP2C9TMEM97SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 P2RY14 3559/4885TSPO 1258/4885CYP2C9 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.